The IASLC 2023 World Conference on Lung Cancer offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of lung cancer and thoracic oncology. Over 7,000 clinicians and scientists from around the world are expected to attend. Increase your visibility and organization’s profile by becoming a Sponsor and/or Exhibitor or by holding an Industry Supported Symposium at this outstanding and important Conference.
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
ACT Genomics is an innovation-driven cancer solution provider with offices in Taipei, Hong Kong, Singapore, Tokyo, Bangkok and Wales (UK). With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we “Turn Genomics into Action”. To learn more about ACT Genomics, visit www.actgenomics.com.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies and has reached millions of patients globally.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a. For more information about its clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary, global oncology organizations. Through research, education, and promotion of the highest quality, equitable patient care, members work to create a world where cancer is prevented or cured, and every survivor is healthy.
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company’s focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
BeiGene is a global biotechnology company with a mission to ensure medicines are accessible to people facing cancer and life-threatening diseases, wherever they live. Our founding belief is that there is a better way to bring medicines to patients around the world. As a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. United by a sense of urgency and a commitment to reach far more patients around the world Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Basel, Beijing and Cambridge, Mas., yet this is just the beginning. That’s why we say, “Cancer has no borders, and neither do we.” https://www.beigene.com/
Boehringer Ingelheim International Gmbh
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.
Burning Rock Dx
Burning Rock Dx (NASDAQ: BNR) is committed to providing NGS-based testing for cancer patients, biomarker detection and companion diagnostic development services to pharmaceutical partners, and NGS-based multi-cancer early detection testing.
We focus on providing tumor genomic data solutions, clinical trial solutions, integrated CDx development, and precision patient recruitment for pharmaceutical companies, thereby efficiently facilitating the entire process of anti-cancer drug development.
Coreline Soft is a leading AI solution company specializing in CT image analysis. Our flagship product, aview, offers a range of innovative solutions for lung cancer screening and other pulmonary diseases. With global recognition and partnerships with prestigious medical institutions, Coreline is revolutionizing the field of CT imaging, empowering medical professionals, and enhancing early detection of cancer worldwide. https://www.corelinesoft.com/en/
Daiichi Sankyo, Inc.
With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.
As a family-owned and operated business, Erbe develops, manufactures and markets surgical systems for professional use in various medical disciplines all over the world. Erbe technology leads the market in many countries and is therefore an inherent part of the working processes in the OR. The products are thus helping to provide the best possible treatment for patients. The portfolio comprises devices and instruments for electrosurgery, thermofusion, plasmasurgery, cryosurgery and hydrosurgery. By combining these technologies, innovative applications become possible, particularly in general surgery, gastroenterology, gynecology, pulmonology and urology. Erbe employs more than 1000 people worldwide, over 650 of them in Germany. Approx. 170 employees work in research and development. The intensive collaboration with renowned users from medical schools and hospitals is the key to success with which Erbe successfully furthers developments in medicine. https://de.erbe-med.com/de-en/
Gilead and Kite Oncology are creating the future of oncology. From ADCs and small molecules to cell therapy, our R&D programs and partnerships are focused on helping to bring more life to people with cancer and changing the way cancer is treated.
GSK is committed to maximising patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, tumour cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, and antibody-drug conjugates, either alone or in combination.
Guardant Health AMEA is a wholly owned subsidiary of Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for patients with advanced-stage cancer, and Guardant Reveal™ for patients with early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealthamea.com and follow the company on LinkedIn, Twitter and Facebook.
Janssen Asia Pacific
At Janssen Oncology, we have a bold vision – the elimination of cancer.
This is what drives us to push the boundaries of science to help patients live cancer-free for longer than ever before.
On the back of 30 years of innovation in oncology1, our first-in-class therapies in solid tumors and hematological malignancies have extended lives and established new standards of care.
Yet we continue to pursue every avenue to suppress, destroy and ultimately eliminate cancer – seeking not just incremental, but monumental change as we concentrate on where we can make the biggest difference. It is this focus on the needs of patients and their families that has propelled us to be among the top 5 and fastest growing oncology companies globally1, with no less than ten transformational therapies approved in the last decade1.
We focus on making hope and possibility a reality. Harnessing cutting-edge research platforms for personalized medicines, we continue to pursue the most compelling science to give an increasing number of people more time to live well, live longer and live cancer-free.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Asia Pacific, a division of Johnson and Johnson International (Singapore) is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
At MSD, our goal is to translate breakthrough science into innovative oncology medicines. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry. https://www.msd.com/
NGeneBio Co., Ltd. provides precision diagnostic solution that combines diagnostics and big data technology.
NGS cancer panel received 26 Patents and has a worldwide sales network in over 20 countries.
NGeneBio is a leading global provider in the precision diagnostic industry. https://www.ngenebio.com
At Olympus, we focus on improving patient care quality. We do this through developing and designing world-leading, clinically advanced, precision technologies and services. We care about achieving the best results in lung cancer diagnosis, and our passion has translated into our portfolio of minimally invasive lung cancer solutions to help tackle this devastating disease today and in the future.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
For more information, please visit www.roche.com.
Roche in Oncology
Our mission has been to turn science into breakthroughs to deliver better outcomes for everyone facing a cancer diagnosis. Today, we’re studying treatments for a wide array of cancers, with nearly 150 ongoing clinical trials and 22 breakthrough therapy designations in oncology. Our research is backed by our investment of over 13B CHF in R&D, more than any other healthcare company in the world.
We are committed to personalising cancer care for all patients and continue to focus on developing innovative medicines across various types of haematologic malignancies and solid tumours. We are leveraging multiple treatment approaches, including targeted therapies, cancer immunotherapies, cell and gene therapies, and next generation vaccines, and bringing innovation into earlier stages of disease to maximise a chance of cure.
At Sanofi, we recognize the burden that cancer places on individuals and those who care for them. Their stories motivate and inspire us in our mission to develop novel treatment options, expand access to therapies, provide comprehensive patient support resources, and work with patient organizations worldwide to fully understand both patient and caregiver needs, and impact the lives of people living with many different types of cancer. Learn more at www.sanofi.com
Celebrating Over 100 Years and Our Journey Continues!
Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Proudly crafting Scanlan® LEGACY Needle Holders and Forceps; featuring our new revolutionary Scan- II™ handle design. Full line Scanlan® VATS instruments including D’Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps and Khan Decortication Grasper.
Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.
ESTS is the largest international general thoracic surgery organisation with more than 1650 members from all continents. The Society’s mission is to improve quality in the specialty, from clinical and surgical management of patients to education, training and credentialing of thoracic surgeons worldwide.
For information on exhibit opportunities, please contact:
For more information regarding promotion & advertising, symposium, and exhibit opportunities, please contact:
International Association for the Study of Lung Cancer (IASLC)
Phone: +1 720 598 1951
Fax: +1 720 325 2848